ClinicalTrials.gg
CompletedNCT01541371Updated Aug 7, 2013Results posted

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

A Phase 3 interventional study of Paliperidone ER in Schizophrenia, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
26th of 115
405 · median 178
Started
2008
with 12 others
Phase 3
41 of 115
none open now
Registered
72nd of 115
by date
Lead sponsor
4 of 115
Xian-Janssen Pharmaceutical Ltd.

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 26th largest by enrollment, is one of 13 that started in 2008, is one of 41 in phase 3, and was the 72nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions [a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into the self) who were not satisfied with other prior antipsychotics (agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect; olanzapine, quetiapine and risperidone) they had been taking. The safety and tolerability of paliperidone ER tablets will also be assessed.

Read the detailed description

This is an open label (all people know the identity of the intervention), prospective (study following participants forward in time), non-randomized (the study drug is not assigned by chance, participants may choose which group they want to be in, or they may be assigned to the groups by the researchers), single-arm (getting one dose of medicine) and multi-center (when more than one hospital or medical school team work on a medical research study) study designed to determine the efficacy, tolerability and safety of flexible dosage of paliperidone ER tablets in treatment of participants with schizophrenia not satisfied with other prior antipsychotics. The duration of the study will be 12 weeks. All participants will be given paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks; initial dose for paliperidone ER will be 6 mg/day. The primary objective will be to evaluate the efficacy of treatment with paliperidone ER using Positive and Negative Symptom Scale (PANSS) total scores. Participants safety and tolerability will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone extended-release tablets
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants meeting -IV (DSM-IV) diagnosis criteria of schizophrenia
  • Participant receiving full course of treatment (6-8 weeks) at correct dose (dose range recommended by the instruction) of Risperdal, Zyprexa or Seroquel before enrollment, was poorly controlled and had to change medication because of unsatisfying efficacy, tolerability or safety issues, or other reason
  • Participant in the non-acute phase during screening received treatment with any of above three antipsychotics within 4 weeks before enrollment and state of illness was relatively stable
    1. Female participants must be for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of before entry and throughout the study. Effective methods of birth control include prescription hormonal contraceptives, contraceptive injections, intrauterine devices, double barrier method, contraceptive patch and male partner sterilization. Female participants must also have a negative urine pregnancy test at screening
  • Participant willing to and who could complete questionnaire by himself

Exclusion criteria

Exclusion Criteria:

  • Participant receiving treatment with clozapine or risperidone microspheres for injection (Hengde) within 3 months before screening
  • Participant having history of seizure except febrile convulsion (seizures that occur during a febrile episode [fever])
  • Participant having schizophrenia (previous treatment with unsatisfied efficacy of 2 or more than 2 kinds of antipsychotics with different chemical structure after adequate dose and duration)
  • Participant receiving electric shock treatment within 1 month before screening
  • Participant having serious, unstable physical diseases
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Paliperidone ER

    Drug: Paliperidone ER

Interventions

  • Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12

    PANSS is a medical scale that assesses various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\] and hallucinations \[imagining things\], and withdrawal into the self). The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Week 12

    PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Positive syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. Negative syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. General Psychopathology subscale ranges from 16 to112, higher change scores indicate worsening.

    Time frame: Baseline and Week 12

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 12

    The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28. Higher change score indicates greater severity.

    Time frame: Baseline and Week 12

  3. Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score

    PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Percentage of participants with at least 20 percent improvement of PANSS total score was measured.

    Time frame: Week 12

  4. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 12

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher change scores indicate worsening.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12

    PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\<30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline and Week 12

  6. Number of Participants With Satisfaction With the Study Treatment

    Participants assessed their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).

    Time frame: Baseline and Week 12

  7. Change From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Week 12

    The self-administered sleep VAS scale (0-100 milimeter \[mm\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).

    Time frame: Baseline and Week 12

07

Results

Posted Aug 7, 2013

Participant flow

Participants were recruited from 19 study centers between 30 July 2008 and 23 September 2009.

Participant flow — Overall Study
MilestonePaliperidone Extended Release (ER)
Started403
Full analysis set394
Completed326
Not completed77
Withdrew: Withdrawal by subject14
Withdrew: Lost to follow-up21
Withdrew: Adverse event15
Withdrew: Lack of efficacy12
Withdrew: Protocol violation6
Withdrew: Study medication non-compliance3
Withdrew: Other6

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12

PANSS is a medical scale that assesses various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\] and hallucinations \[imagining things\], and withdrawal into the self). The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).

Time frame:
Baseline and Week 12
Reported as:
Mean · unit on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12
unit on a scaleLack of Efficacy GroupLack of Tolerability GroupOther Group
Baseline77.18 ± 17.5058.46 ± 16.3163.33 ± 19.08
Change at Week 12-26.29 ± 20.77-13.99 ± 15.74-20.90 ± 18.20
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Week 12

PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Positive syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. Negative syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. General Psychopathology subscale ranges from 16 to112, higher change scores indicate worsening.

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Week 12
Units on a scalePaliperidone Extended Release (ER)
Positive: Baseline17.07 ± 6.53
Positive: Change at Week 12-6.59 ± 6.30
Negative: Baseline18.57 ± 6.66
Negative: Change at Week 12-6.14 ± 5.99
General psychopathology: Baseline34.44 ± 9.75
General psychopathology: Change at Week 12-10.84 ± 10.21
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 12

The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28. Higher change score indicates greater severity.

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 12
Units on a scalePaliperidone Extended Release (ER)
Positive symptoms: Baseline21.61 ± 7.15
Positive symptoms: Change at Week 12-8.16 ± 7.18
Negative symptoms: Baseline19.15 ± 7.10
Negative symptoms: Change at Week 12-6.53 ± 6.60
Disorganized thoughts: Baseline14.13 ± 4.65
Disorganized thoughts: Change at Week 12-4.13 ± 4.28
Uncontrolled hostility/excitement: Baseline7.73 ± 3.83
Uncontrolled hostility/excitement:Change at Week12-2.74 ± 3.63
Anxiety/depression: Baseline7.45 ± 2.76
Anxiety/depression: Change at Week 12-2.00 ± 2.67
SecondaryPercentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score

PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Percentage of participants with at least 20 percent improvement of PANSS total score was measured.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score
Percentage of participantsLack of Efficacy GroupLack of Tolerability GroupOther Group
Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score65.97 (59.95 to 71.99)51.72 (42.63 to 60.82)61.90 (47.22 to 76.59)
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 12

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants". Higher change scores indicate worsening.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 12
units on a scaleLack of Efficacy GroupLack of Tolerability GroupOther Group
Baseline (n=237,115,41)4.54 ± 0.913.20 ± 1.113.86 ± 1.09
Change at Week 12 (n=208,103,40)-1.77 ± 0.09-1.01 ± 0.14-1.66 ± 0.23
SecondaryChange From Baseline in Total Personal and Social Performance (PSP) Score at Week 12

PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\<30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline and Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12
Units on a scaleLack of Efficacy GroupLack of Tolerability GroupOther Group
Baseline (n=238,115,41)53.16 ± 13.7966.95 ± 12.8966.00 ± 11.21
Change at Week 12 (n=205,106,40)18.57 ± 16.8710.09 ± 13.7512.40 ± 13.33
SecondaryNumber of Participants With Satisfaction With the Study Treatment

Participants assessed their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).

Time frame:
Baseline and Week 12
Reported as:
Number · Participants
Number of Participants With Satisfaction With the Study Treatment
ParticipantsLack of Efficacy GroupLack of Tolerability GroupOther Group
Baseline, Very satisfied (n=230,113,41)130
Baseline, Satisfied (n=230,113,41)153015
Baseline, Generally satisfied (n=230,113,41)845825
Baseline, Dissatisfied (n=230,113,41)124211
Baseline, Very dissatisfied (n=230,113,41)610
Week 12, Very satisfied (n=208,105,40)302310
Week 12, Satisfied (n=208,105,40)935118
Week 12, Generally satisfied (n=208,105,40)622410
Week 12, Dissatisfied (n=208,105,40)2362
Week 12, Very dissatisfied (n=208,105,40)010
SecondaryChange From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Week 12

The self-administered sleep VAS scale (0-100 milimeter \[mm\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).

Time frame:
Baseline and Week 12
Reported as:
Mean · mm
Change From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Week 12
mmLack of Efficacy GroupLack of Tolerability GroupOther Group
Quality of sleep score: Baseline (n=233,115,41)60.76 ± 26.7075.89 ± 20.2470.31 ± 22.40
Quality of sleep: Change at Week 12 (n=202,106,40)15.76 ± 29.462.90 ± 27.4113.60 ± 26.94
Daytime drowsiness score: Baseline (n=233,115,41)38.16 ± 23.7044.77 ± 25.2934.26 ± 23.64
Daytime drowsiness:Change at Week 12(n=202,106,40)-15.76 ± 27.52-21.66 ± 27.88-18.10 ± 26.87

Adverse events

Collected over Baseline up to Week 12. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Extended Release (ER)—1/403 (0.2%)227/403 (56.3%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Extended Release (ER)
DepressionPsychiatric disorders1/403
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPaliperidone Extended Release (ER)
AkathisiaPsychiatric disorders74/403
TremorNervous system disorders52/403
DystoniaNervous system disorders35/403
SomnolencePsychiatric disorders32/403
InsomniaPsychiatric disorders26/403
Extrapyramidal disorderNervous system disorders24/403
Weight increasedInvestigations17/403
DizzinessNervous system disorders17/403
NauseaGastrointestinal disorders15/403
Upper respiratory tract infectionInfections and infestations15/403

Baseline characteristics

Age Continuous
Age Continuous(Years)Paliperidone Extended Release (ER)
Mean30.88 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Extended Release (ER)
Female199
Male195
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2012
First posted
Feb 29, 2012
Start
Jul 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Aug 7, 2013
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01541371
Responsible party
Sponsor
First posted
Feb 29, 2012
Start date
Jul 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Aug 7, 2013
Last update
Aug 7, 2013

Study contacts

Xian-Janssen Pharmaceutical Ltd., China Clinical Trial
study director · Xian-Janssen Pharmaceutical Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion